Press Release: Novartis to acquire Xiidra(R), -2-

09.05.19 00:19 Uhr

Werte in diesem Artikel
Aktien

96,23 CHF -2,98 CHF -3,00%

globally and we are finding innovative ways to expand access to our

latest treatments. About 105 000 people of more than 140 nationalities

Wer­bung

work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

http://twitter.com/novartis

For Novartis multimedia content, please visit

www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

Wer­bung

References

[1] Novartis International AG. (2018). Novartis Q4 and FY 2018

Condensed Financial Report - Supplementary Data. Retrieved from:

https://www.novartis.com/sites/www.novartis.com/files/2019-01-financial-report-en.pdf.

[2] FDA. Xiidra (lifitegrast ophthalmic solution). Prescribing

information. Available at:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208073s000lbl.pdf.

Wer­bung

Accessed April 25, 2019.

[3] Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the

beaver dam offspring study: prevalence, risk factors, and health-related

quality of life. Am J Ophthalmol. 2014;157(4):799-806.

doi:10.1016/j.ajo.2013.12.023.

[4] American Optometric Association. Dry Eye. Available at:

https://www.aoa.org/patients-and-public/eye-and-vision-problems/glossary-of-eye-and-vision-conditions/dry-eye#1.

Accessed April 25, 2019.

[5] Sheppard AL, Wolffsohn JS. Digital eye strain: prevalence,

measurement and amelioration. BMJ Open Ophthalmol. 2018;3(1):e000146.

doi:10.1136/bmjophth-2018-000146.

[6] Bradley JL, Özer Stillman I, Pivneva I, et al. Dry eye

disease ranking among common reasons for seeking eye care in a large US

claims database. Clin Ophthalmol. 2019;13:225-232.

doi:10.2147/OPTH.S188314.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Amy Wolf Peter Zuest

Global Head Communications, Ophthalmology Novartis Global Media Relations

+41 61 696 58 94 (direct) +41 79 899 9812 (mobile)

+41 79 576 07 23 (mobile) peter.zuest@novartis.com

amy.wolf@novartis.com

Eric Althoff

Novartis US External Communications

+1 646 438 4335

eric.althoff@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 862 778-3275

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 862 778-3258

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2243879/885977.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

May 08, 2019 18:20 ET (22:20 GMT)

Ausgewählte Hebelprodukte auf Novartis

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novartis

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Novartis AG

Wer­bung

Analysen zu Novartis AG

DatumRatingAnalyst
04.07.2025Novartis BuyDeutsche Bank AG
03.07.2025Novartis NeutralUBS AG
02.07.2025Novartis NeutralGoldman Sachs Group Inc.
01.07.2025Novartis NeutralUBS AG
19.06.2025Novartis BuyDeutsche Bank AG
DatumRatingAnalyst
04.07.2025Novartis BuyDeutsche Bank AG
19.06.2025Novartis BuyDeutsche Bank AG
09.06.2025Novartis BuyDeutsche Bank AG
30.04.2025Novartis BuyDeutsche Bank AG
30.04.2025Novartis KaufenDZ BANK
DatumRatingAnalyst
03.07.2025Novartis NeutralUBS AG
02.07.2025Novartis NeutralGoldman Sachs Group Inc.
01.07.2025Novartis NeutralUBS AG
16.06.2025Novartis NeutralUBS AG
12.06.2025Novartis HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
21.11.2024Novartis UnderweightBarclays Capital
24.06.2024Novartis UnderweightBarclays Capital
23.04.2024Novartis UnderweightBarclays Capital
28.03.2024Novartis UnderweightBarclays Capital
06.02.2024Novartis UnderweightBarclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen